

April 10, 2020

Listing Department  
**BSE Limited**  
P J Towers, Dalal Street, Fort,  
Mumbai – 400001

**Code: 532321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai – 400051

**Code: CADILAHC**

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a Press Release dated April 10, 2020 titled “Zydus receives tentative approval from USFDA for Empagliflozin Tablets”.

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors’ at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

## Zydus receives tentative approval from the USFDA for Empagliflozin Tablets

---

*Ahmedabad, April 10, 2020*

Zydus Cadila has received tentative approval from the USFDA to market Empagliflozin Tablets, in the strengths of 10 mg and 25 mg (US RLD: Jardiance® Tablets).

The medication is used together with diet and exercise to improve blood sugar control in adults with Type 2 diabetes mellitus. It is also used to reduce the risk of cardiovascular death in adult patients with Type 2 diabetes mellitus and established cardiovascular disease.

The drug will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 286 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zydus Cadila**

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

\*\*\*